Pharmesis International Ltd. Stock

Equities

BFK

SG1BH6000003

Pharmaceuticals

Market Closed - Singapore S.E. 04:37:49 2024-04-26 am EDT 5-day change 1st Jan Change
0.12 SGD +50.00% Intraday chart for Pharmesis International Ltd. +50.00% +22.45%

Financials

Sales 2022 50.37M 6.95M 9.47M Sales 2023 45.64M 6.3M 8.58M Capitalization 14.45M 1.99M 2.72M
Net income 2022 -3M -414K -564K Net income 2023 -4M -552K -752K EV / Sales 2022 0.19 x
Net cash position 2022 3.18M 440K 599K Net Debt 2023 7.05M 973K 1.33M EV / Sales 2023 0.47 x
P/E ratio 2022
-3.63 x
P/E ratio 2023
-2.79 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 22.66%
More Fundamentals * Assessed data
Dynamic Chart
1 day+50.00%
1 week+50.00%
Current month-8.40%
1 month-8.40%
3 months+34.83%
6 months+39.53%
Current year+22.45%
More quotes
1 week
0.09
Extreme 0.085
0.12
1 month
0.08
Extreme 0.08
0.12
Current year
0.08
Extreme 0.08
0.14
1 year
0.08
Extreme 0.08
0.15
3 years
0.08
Extreme 0.08
0.22
5 years
0.08
Extreme 0.08
0.63
10 years
0.08
Extreme 0.08
0.63
More quotes
Managers TitleAgeSince
Chief Executive Officer - 04-04-15
Corporate Secretary - 22-05-29
Comptroller/Controller/Auditor - 16-05-31
Members of the board TitleAgeSince
Chairman 73 05-11-08
Chief Executive Officer - 04-04-15
Director/Board Member 35 23-07-30
More insiders
Date Price Change Volume

Delayed Quote Singapore S.E., April 26, 2024 at 04:37 am EDT

More quotes
Pharmesis International Ltd. is a Singapore-based investment holding company. The Company is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.
More about the company